July to September

• Net sales amounted to MSEK 0 (0)

• Net loss was MSEK -3.9 (-5.3), corresponding to earnings per share of SEK -0.06 (-0.09)

• Cash flow after financing activities amounted to MSEK -1.3 (-6.1)

• Cash amounted to MSEK 3.9 (23.5), compared to MSEK 17.8 on 31 December 2022

January to September

• Net sales amounted to MSEK 0.1 (0)

• Net loss was MSEK -14.7 (-19.9), corresponding to earnings per share of SEK -0.24 (-0.33)

• Cash flow after financing activities amounted to MSEK -13.9 (-21.8)

 
Significant events during January – September

• In February, the milestone Clean file was reached in PHSU05.

• In April the results from the company's Phase II study PHSU05 were announced. No clear differences in the efficacy on reducing the scarring were observed between ensereptide and placebo.

• In May, the company received a limited capital adequacy guarantee (Sw:” kapitaltäckningsgaranti”) to cover for working capital needs for the remainder of 2023.

• In June, the company informed that a number of measures had been taken to reduce the Company's costs, which included the discontinuation of the ensereptide project and the termination of the Company's key personnel.

• In August it was reported that Promore engages Erik Penser Bank as liquidity provider.

Events after the reporting period

• In October the company announced the initiation of a voluntary liquidation.

” In my role as liquidator, I continue to review opportunities for a strategic transaction supported by the management team of the company that have been given notice of termination quote.”

Lars-Henrik Andersson, Liquidator